Cargando…

A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4(+) T-cells

Human immunodeficiency virus type 1 (HIV-1) latency is a major barrier to a cure of AIDS. Latently infected cells harbor an integrated HIV-1 genome but are not actively producing HIV-1. Histone deacetylase (HDAC) inhibitors, such as vorinostat (SAHA), have been shown to reactivate latent HIV-1. AR-4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mates, Jessica M., de Silva, Suresh, Lustberg, Mark, Van Deusen, Kelsey, Baiocchi, Robert A., Wu, Li, Kwiek, Jesse J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739806/ https://www.ncbi.nlm.nih.gov/pubmed/26855567 http://dx.doi.org/10.4137/RRT.S31632

Ejemplares similares

Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice
por: Chua, Ming Jang, et al.
Publicado: (2021)

Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors
por: Sahu, Gautam K, et al.
Publicado: (2011)

Identification of Combinations of Protein Kinase C Activators and Histone Deacetylase Inhibitors that Potently Reactivate Latent HIV
por: Curreli, Francesca, et al.
Publicado: (2020)

Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways
por: Chen, Yi-Jin, et al.
Publicado: (2017)

The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors
por: Elshafae, Said M., et al.
Publicado: (2021)

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42()()
por: Henderson, Sally E., et al.
Publicado: (2016)

Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas
por: Welling, D. Bradley, et al.
Publicado: (2021)

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
por: Lucas, David M., et al.
Publicado: (2010)

Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
por: Guzman, Monica L., et al.
Publicado: (2014)

Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1
por: Martínez-Bonet, Marta, et al.
Publicado: (2015)

In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors
por: Banga, Riddhima, et al.
Publicado: (2016)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

PRMT5 Is Upregulated in HTLV-1-Mediated T-Cell Transformation and Selective Inhibition Alters Viral Gene Expression and Infected Cell Survival
por: Panfil, Amanda R., et al.
Publicado: (2015)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

The histone deacetylase Hos2 forms an Hsp42-dependent cytoplasmic granule in quiescent yeast cells
por: Liu, I-Chun, et al.
Publicado: (2012)

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2015)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Barman, Madhumanti, et al.
Publicado: (2021)

Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2023)

Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation
por: Albert, Brice J., et al.
Publicado: (2017)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Euphorbia Kansui Reactivates Latent HIV
por: Cary, Daniele C., et al.
Publicado: (2016)

The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses
por: Moreira, José Manuel Afonso, et al.
Publicado: (2003)

Histone deacetylases 1 and 2 restrain CD4(+) cytotoxic T lymphocyte differentiation
por: Preglej, Teresa, et al.
Publicado: (2020)

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat
por: Maxwell, Jill W., et al.
Publicado: (2020)

Homeostatically Maintained Resting Naive CD4(+) T Cells Resist Latent HIV Reactivation
por: Tsunetsugu-Yokota, Yasuko, et al.
Publicado: (2016)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
por: Hai, Yang, et al.
Publicado: (2017)

Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Jaime-Ramirez, Alena C., et al.
Publicado: (2017)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylases in RA: epigenetics and epiphenomena
por: Grabiec, Aleksander M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_i7gi053g2kocqiie3fgit9ig2r